针对精神病性障碍的聚焦自杀心理干预的作用机制与疗效:认知方法对抗自杀(CARMS)多中心评估者设盲随机对照试验
在四家英国国家医疗服务体系(NHS)站点开展多中心、评估者设盲随机对照试验,纳入329例非情感性精神病且近3个月有自杀体验的成人,1:1随机分配至常规治疗组或认知行为自杀预防(CBSPp)联合常规治疗组。6个月时两组自杀意念严重程度(ASIQ)无统计学差异(p=0.07;Cohen's d -0.20,95%CI -0.42至0.02)。中介分析显示治疗通过改善社会支持评价产生显著间接效应(-2.85,95%CI -7.00至-0.23),进而降低6个月自杀意念严重程度。
要点
- 6个月时CBSPp组与对照组ASIQ自杀意念严重程度无统计学差异(p=0.07;Cohen's d -0.20,95%CI -0.42至0.02)。
- 治疗通过增强社会支持评价产生显著间接中介效应(-2.85,95%CI -7.00至-0.23),进而降低6个月自杀意念严重程度。
- 治疗组26例发生132次自杀未遂,对照组30例发生91次自杀未遂,为最常见严重不良事件;4例死亡均非自杀且与治疗无关。
核心结论
- CBSPp在6个月时对自杀意念无效果,但通过改善社会支持评价产生了显著的间接效应。
研究设计与样本
- 多中心、评估者设盲随机对照试验,在英国四家NHS站点开展,2017年6月21日至2020年11月25日招募,最终12个月评估于2022年1月10日完成。
- 479例筛查,329例(69%)知情同意并入组,69例失访后292例随机分配至治疗组149例(51%)和对照组143例(49%),按抗抑郁药使用和NHS站点分层,1:1比例。
- 纳入标准为18岁及以上、符合ICD-10非情感性精神病(F20-F29)、招募前3个月自报自杀体验、接受NHS精神卫生服务团队照护、未参加类似试验的心理治疗、英语能力足以无需翻译参与、能提供知情同意。
- 治疗组约接受24次一对一治疗,通常每周一次,每次约50分钟;评估在基线、第6个月和第12个月进行;主要结局为25条目成人自杀意念问卷(ASIQ)从基线至第6个月的自杀意念严重程度变化,采用意向性治疗人群混合模型分析。
- 中介分析采用计划好的间接线性回归模型,检验6个月时不良社会支持评价、情绪困难、人际问题解决困难、挫败感、被困感和绝望感作为中介变量,以分配条件(治疗vs对照)为预测变量、6个月ASIQ自杀意念严重程度为结局变量,并控制中介变量和结局变量的基线水平。
主要发现
- 6个月时治疗组(n=136)与对照组(n=116)自杀意念严重程度无统计学差异(p=0.07;Cohen's d -0.20,95%CI -0.42至0.02)。
- 显著间接中介效应(-2.85,95%CI -7.00至-0.23)显示治疗增强了社会支持评价,进而使治疗组6个月自杀意念严重程度较对照组降低更多。
- 自杀未遂为最常见严重不良事件:治疗组26例发生132次自杀未遂,对照组30例发生91次自杀未遂。
- CARMS研究中共4例死亡,无一例为自杀或被认为与治疗相关。
关键数值与推荐
- 主要结局为25条目成人自杀意念问卷(ASIQ)评估的自杀意念严重程度,比较基线至第6个月变化。
- 6个月时治疗组(n=136)vs对照组(n=116)ASIQ自杀意念严重程度无统计学差异(p=0.07;Cohen's d -0.20,95%CI -0.42至0.02)。
- 中介间接效应为-2.85(95%CI -7.00至-0.23),中介变量为6个月时社会支持评价。
临床怎么用
- 作者认为,探索如何在精神卫生服务中开发和实施聚焦自杀的治疗,以最大程度增强社会支持和社会连接评价并使其持久,具有重要意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is a need for theoretically grounded and testable suicide-focused psychological therapies, especially in people with severe mental health problems, specifically non-affective psychosis. We aimed to test both the underlying mechanisms and efficacy of a suicide-focused therapy, cognitive behavioural suicide prevention for psychosis (CBSPp). METHODS: We did a multicentre, assessor-masked, randomised controlled trial conducted at four UK National Health Service (NHS) sites. Participants were eligible for enrolment if they were 18 years or older; met ICD-10 criteria for non-affective psychosis (F20-F29); had self-reported suicidal experiences in the 3 months before recruitment; were under the care of an NHS mental health services team; were not receiving a psychological therapy as part of a similar trial; had sufficient competency in the English language not to need an interpreter to participate; and were able to give informed consent. After screening for eligibility and completion of baseline assessments, participants were randomly allocated in a 1:1 ratio to either the treatment as usual group (control) or CBSPp therapy plus standard treatment group (treatment), with stratification by use of antidepressant medication and NHS site. Randomisation took place using an online Sealed Envelope randomisation procedure conducted and overseen by the Manchester Academic Health Sciences Centre Clinical Trials Unit (MCTU). This system was accessed only by specially allocated staff (eg, the CARMS Trial Manager or the MCTU Trial manager). When the system randomly allocated a participant, an unmasked email confirmation was sent to the unmasked coprincipal investigator and the CARMS Trial Manager (also unmasked). Assessors, the trial statistician, and one coprincipal investigator were masked to allocation group. Participants were informed of their randomised allocation group by an unmasked CARMS staff member. Experts-by-experience were involved in all stages of the research. For those in the treatment group, approximately 24 one-to-one therapy sessions were offered, usually weekly, for around 50 min per session. Assessments were conducted at baseline, month 6, and month 12. The primary outcome was suicide ideation severity measured by the 25-item Adult Suicide Ideation Questionnaire (ASIQ), assessed at month 6 relative to baseline. Outcome analyses used mixed models in the intention-to-treat population. Planned mediation indirect linear regression models examined appraisals of poor social support, emotional difficulties, interpersonal problem-solving difficulties, defeat, entrapment, and hopelessness as mediators at 6 months with allocation condition (treatment vs control) as the predictor variable and suicidal ideation severity (ASIQ) at 6 months as the outcome variable, whilst controlling for baseline levels of the mediator and outcome variables. The trial was registered before recruitment at ClinicalTrials.gov (NCT03114917) and ISRCTN (ISRCTN17776666) and is complete. FINDINGS: We recruited participants from four NHS sites from June 21, 2017, to Nov 25, 2020, with the final 12-month assessment completed on Jan 10, 2022. 479 participants were screened for eligibility, and of these 329 (69%) provided consent and were enrolled. After 69 participants were lost to follow-up, 292 participants were randomly allocated to the treatment and control groups (149 [51%] and 143 [49%], respectively). At baseline, 161 (55%) participants were male and 130 (45%) were female; one participant (<1%) in the treatment group was missing gender data. Mean age was 35·1 years (SD 13·2; range 18-69), and 247 (85%) were White or Caucasian. Severity of suicidal ideation was not statistically different between the treatment (n=136) and the control groups (n=116) at 6 months (p=0·07; Cohen's d -0·20 [95% CI -0·42 to 0·02]). A significant indirect mediation effect (-2·85, -7·00 to -0·23) showed that therapy strengthened social support appraisals which, in turn, reduced suicidal ideation severity at 6 months more in the treatment group than in the control group. Suicide attempts were the most frequent severe adverse event (132 attempts in 26 participants in the treatment group vs 91 attempts in 30 participants in the control group). There were four deaths in the CARMS study, none of which were by suicide or considered related to treatment. INTERPRETATION: CBSPp had no effect on suicidal ideation at 6 months, but it did have a significant indirect effect via improving appraisals of social support. It is important to explore how suicide-focused therapies can be developed and implemented in mental health services so that they maximally enhance appraisals of social support and social connection in ways that endure. FUNDING: Efficacy and Mechanism Evaluation Programme, a Medical Research Council and National Institute for Health and Care Research partnership (reference number: 13/161/25).
引用
- Gooding P, Pratt D, Edwards D, et al. Underlying mechanisms and efficacy of a suicide-focused psychological intervention for psychosis, the Cognitive Approaches to Combatting Suicidality (CARMS): a multicentre, assessor-masked, randomised controlled trial in the UK. Lancet Psychiatry. 2025. PMID: 39827886. doi:10.1016/S2215-0366(24)00399-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。